Olema Pharmaceuticals, Inc.於2006年8月7日在特拉華州註冊成立。該公司是一家臨床階段的生物製藥公司,專註於為乳腺癌開發下一代靶向療法。其主要候選藥物palazestrant是一種口服小分子,具有雌激素受體拮抗劑和降解劑的雙重活性,目前正在針對ER+/HER2-轉移性乳腺癌進行3期試驗。
董事
名稱
職位
Sean Bohen
President,Principal Financial Officer,Chief Executive Officer and Director
イアンクラーク
Chairperson of the Board
Andrew Rappaport
Director
Cynthia Butitta
Director
Cyrus L. Harmon
Director
Gorjan Hrustanovic
Director
Graham Walmsley
Director
Sandra Horning
Director
Scott Garland
Director
Yi Larson
Director
股東
名稱
職位
Sean Bohen
President,Principal Financial Officer,Chief Executive Officer and Director
David C. Myles
Chief Discovery and Non-Clinical Development Officer